Please note that this conference is being recorded. I now hand the conference over to Ms. Isha Lamba, Head, Investor Relations and M&A. Thank you, and over to you, Ms. Lamba.
Good afternoon, ladies and gentlemen. On behalf of the management of Dabur India Limited, I welcome you to the E earnings Conference Call pertaining to the Results for Q1 FY2026 Present here with me are Mr. Mohit Malhotra, Chief Executive Officer, Mr. Ankush Jain, Chief Financial Officer, Ms. Gagan Ahluwalia, VP Corporate Affairs, and Mr. N. Krishnan, GM Finance. We will start with an overview of the coppany's performance by Mr. Mohit Malhotra, and this will be followed by a Q&A session. I now hand over to Mr. Mohit Malhotra.
Thank you, Isha. Good evening, ladies and gentlemen. We welcome you to Dabur India Limited's conference call pertaining to the results for the quarter ending 31st July 2025. The quarter witnessed sequential improvement in domestic and international markets despite challenges posed by unseasonal rainfall and geopolitical headwinds. In India, rural markets continued to outperform urban for the fifth consecutive quarter, sustaining its strong growth momentum. Even the urban markets witnessed sequential recovery vis-à-vis last quarter. Our international business remained resilient, delivering a robust double-digit growth. During quarter one of financial year 2026, our seasonal portfolio, comprising beverages and glucose, was impacted due to unseasonal rains and a very short summer. Growth in consolidated sales was around 7%, excluding the seasonal portfolio, while the reported growth was 1.7%, impacted by the seasonal portfolio. India business revenue grew by 4.3%, excluding the seasonal portfolio.
International business exhibited a strong growth of 13.7% in consumer currency and 12.7% in INR terms. Within the domestic business, HPC portfolio performed well with 5% growth. The toothpaste portfolio delivered a growth of 7.3%, led by strong growth in the Red franchise. The herbal segment growth accelerated and outpaced the non-herbal segment by 440 bps, reinforcing the growing consumer preference for Ayurvedic, herbal, and natural oral care offerings. In line with the above trend, we outperformed the toothpaste category growth, leading to sustained market share gains. The home care portfolio delivered a strong growth of 10%, delivered by robust performance in both Odonil and Odomos franchises. Odonil has emerged as the number one brand in the air freshener category with 44% volume market share. The brand recorded 11% growth this quarter, supported by strong double-digit growth in gel pockets and aerosols.
This translated into a market share gain of 183 bps. Our mosquito repellent brand, Odomos, recorded a double-digit growth, aided by early monsoons that positively impacted category demand, resulting in market share gain of 261 bps. Skincare portfolio registered a growth of 9% by Gulabari franchise and Oxylife. In hair oils, we outperformed the category growth and gained market share of 214 bps, taking our total hair oil volume market share to 19%. This is the ever-highest market share that we registered in hair oils. We remained focused on premiumization and expansion into new age offerings in both hair oils and shampoos. In our healthcare portfolio, health supplement, excluding glucose, that got impacted by unseasonal rains grew by 9%. Backed by robust growth in Chyawanprash and honey, the contextual monsoon campaign has worked for the Chyawanprash brand, which reported a growth of 28% with market share gains of 111 bps.
Honey saw a broad-based growth across channels, growing by 11% year-on-year and strengthened its leadership position with a 46 bps gain in market share. Premium variants like Sundarbans and organic honey witnessed good traction. Glucose was severely impacted by rains during the quarter and declined by around 30%. Despite this, we gained market share of 118 bps in the category. In the digestive portfolio, Hajmola franchise reported a 9% growth with variants like Chatkola, Limkola, and Mr. Ram, now contributing around 50% to the overall brand franchise. Recently launched Hajmola soft chews received a good response from the consumers. Pudin Hara brand grew by 7%, driven by a new campaign and renewed focus. Within OTC/ethicals, Honitus registered a growth of 46%, driven by a surge in demand during the monsoon season. Health juices continued on a strong trajectory and grew by 18%.
We are focusing on new contemporary formats across our healthcare portfolio, and some of these products will be introduced in the next few months. JNN category was impacted due to unseasonal rains and business disruption due to Operation Sindoor in key markets of North India, such as Jammu and Kashmir, Himachal, and Punjab. However, our focus on driving the premium portfolio is working well, with Real Active franchise witnessing a robust growth of 20%. We launched coconut water in aseptic PET format this season, which has witnessed exceptional growth, with the brand cornering 25% of the fast-growing coconut water market. Even in the JNN segment, we continued to outperform the category, gaining 207 bps in market share in nectars and 141 bps in 100% juices. Coming to international business, we registered robust growth of 13.7% in consumer currency terms.
This was on the back of a strong growth of 10% in the Middle East-North Africa region, 20% in Sub-Saharan Africa, 40% in the U.K./EU, 30% in the U.S., 36% in Turkey, and 10.2% in Bangladesh. Coming to profitability, in spite of high inflation and seasonal impact, our operating profit and PAT grew ahead of the top line, led by price increase and saving initiatives. This is indicative of the strength and resilience of our brands. Overall, the consolidated growth of 7%, excluding the seasonal portfolio, is quite encouraging, with market share gains across 95% of our portfolio. Looking ahead, we are quite optimistic about a sequential recovery in demand on the back of softening food inflation, favorable monsoon, sustained momentum in rural, and some green shoots which are visible in the urban demand.
Our international business continues to be on a strong trajectory, with currency depreciation now lapping over in most of our geographies. With this, I will conclude my address and open the floor for any Q&A that you may have. Thank you very much.
Thank you very much, sir. We will now begin with the question-and-answer session. Anyone who wishes to ask questions may press star and one on the touchstone phone. If you wish to withdraw yourself from the question queue, you may press star and two. Participants are requested to use only handsets while asking a question. Also, in order to ensure that the management will be able to address questions from all the participants in the conference, kindly limit your questions to two per participant. Should you have a follow-up question, please rejoin the queue. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Mihir Shah from Nomura. Please go ahead.
Hi, sir. Thank you for taking my question. Firstly, I wanted to just highlight that the presentation that we are seeing this quarter versus the historical times, there has been a lot of change in disclosures. We have been tracking this company for more than, I would say, 15- 17 years, a lot of us on the street, and we have never seen less disclosures from Dabur. You've been one of the companies that has highlighted many disclosures across categories. Can we request you to revert back to the earlier disclosure standards so that we can gauge the progress of the company in a much better manner like we have done all these years? That's point number one. As far as my question is concerned, Mohit, there is a favorable base that you are having in the second quarter. There's a 5.5% decline that we had seen last year.
With this ex-off seasonal impact, 7% growth that you are seeing, should one expect high-teens growth to come back from second quarter? Will that be a fair understanding? That's one.
Yeah, Mihir, I want to answer the second question first. I think. Am I audible?
Yeah, Mohit, you're audible [crosstalk].
Yeah, you're absolutely right. Last year, we did some sort of inventory correction in the same quarter last year. There is a little improvement base, but we have no intention of increasing the. We are expecting, depending upon the season or the season pair and how the juices trajectory remains, because the month of July has been quite wet, which has been unprecedented in the past. We are closely observing the situation. We will definitely expect the average growth that we are planning towards the average growth in the second quarter. There never will be a situation that we want to shove in more primary, less than the secondary. I think we are observing the situation. Beverage business will be low single-digit growth only in the coming quarter. The rest of the businesses should fire at double-digits, to your point.
Now, on the first point of disclosures, I would want Isha to address it.
Hi, Mihir. Thanks for your question. We have streamlined certain disclosures in the investor presentation, but this has been based on benchmarking with industry peers. This does help avoid some excessive detail that could pose any kind of competitive sensitivity. We also remain committed to transparency and consistency, and we'll continue to share any meaningful insights via earnings calls, and also maintain this format going forward.
It does also report volume growth, and we are not seeing those in the disclosures for the quarter.
Mihir, I'm sorry to interrupt you. Before you ask your further question, I would request you to mute yourself on webcast, as there is an echo from your line. Please mute your webcast if you are asking a question. Thank you so much. You may proceed with your question now.
Yeah, Isha, volume growth for the quarter. Secondly, I wanted to just check on the margin front. Gross margins continue to be under pressure. We are seeing Amla continuing to be inflationary. Do you foresee any headwinds on the margins, or should one expect some improvement on the gross margin side as well? Yeah, so I think margins, as far as margins are concerned, we don't see any pressure on the margins. There was an inflation of around 7% in the previous quarter, and all the inflation has been mitigated by price increases that we have taken. That talks about resilience and strength of our brand. We mitigated through saving initiatives and some price increases that we've taken. We've taken a 4% or 3%- 4% price increases, and the rest are saving initiatives, which has completely mitigated the impact of inflation that we had on our basket of commodities. That said, the projection of inflation going forward is also very high in the range of around 8%, but we are pretty optimistic of kind of mitigating it through price increases and saving initiatives.
There's a string of initiatives that are lined up going forward in the future, which will mitigate the impact of price. Our gross margins have not got diluted in the previous quarter because the ICAP gross margins remain the same. Because of the competitive intensity, there was a higher netting of schemes. Because of competitive intensity from Colgate and in hair oils also, we had to give a lot of BTL, which got netted off from the top line. Therefore, you see a gross margin dilution in that number. Overall, operating margin has been maintained at the same level. We don't see any gross margin pressure. For the full year, we want our operating margin to only inch up significantly as compared to last year to this year.
Understood, Mohit. On the operating margin front, lastly, I see that you've been able to maintain it, but that is on the back of sharp decline in ad spends, about 15% decline. I also remember that your base had a higher ad spend. Is there any one-off sitting in the base that we are missing out, or one-off sitting in this quarter for ad spends? Should one expect ad spends to continue to be upwards?
Yeah, overall, advertising and promotion expenditure has actually moved up ahead of the top line. That is in the range of around 5% up. We have redirected the money from ATL into BTL. As I've been telling you earlier also, depending on the competitive intensity, the trade inputs are given, consumer schemes and trade schemes. We invested more in consumer and trade, that's why the netting is more and less on media. Going forward, ad-brand investments will continue to be higher, and we want to increase our gross margins and invest in advertising support. There is no one-off sitting in the base. I can just confirm that to you. We will continuously make an endeavor to increase the overall advertising and promotion expenditure going forward also, and investing in brands and distribution.
Got it. Thank you very much, Mohit. Wishing you all the best. I have a few more follow-up questions, which I'll circle back in the queue or probably check with the investor relations team later. Thanks, and wishing you all the best.
Thank you. Thank you [crosstalk].
Thank you. Participants, you may please press star and one to ask questions. The next question is from the line of Prakash Kapadia from Kapadia Financial Services. Please go ahead.
Yeah, thanks for the opportunity. Two questions, Mohit, slightly more longer-term in nature. If I were to look at the healthcare piece after the COVID base of around INR 1,600 crore in 2021, despite all our efforts in smaller packs, newer formats, we've not been able to cross that broader range. What are the challenges we are facing in Honey, Chyawanprash? Because this was our Forte, formulations, higher margins. Is the product lost relevance to the younger population, or has the dynamic changed? You seem to be the leader, but beyond the point of time, the category growth would depend on the leader. Even if I were to take the OTC/ethicals segment, that has also been broadly INR 800 crore, despite all the efforts of the new business head, focus on medical channel, doctor efficacy. Is there a competitive landscape which has changed?
If we have the aspiration and the base to do well, this segment has to grow. What really is the game plan in this segment? Thoughts will be very helpful.
Right, so Prakash, I don't think there's any issue of the category here. Because as I told you, season played a spoil sport for us. Glucose, which is a significant contributor in the first quarter, because of the season, declined by some 40%. The rest of the entire portfolio has done very well. Just to give you an example, Chyawanprash has grown by around 30% for us. Our monsoon campaign has worked well for us. New formats are already contributing to more than around 20% of the business, which are margin equitative to us. We have gained 111 bps of market share in Chyawanprash. Honey, last year, there was some headwind in terms of honey issues, and there were returns coming from the market. Now that's all behind us. The honey has grown by around 11%. Premium variants are doing very well.
There is a 46 bps gain in the market for us, agnostically across segments. Glucose, which is an issue, which got impacted by unfavorable weather conditions. Not just for us, even for Zydus, that's been the case. That's taken out the steam from the growth. If I exclude glucose, then the business has grown by around 4.4%. We've taken a price increase of around 6% in the overall healthcare portfolio. Our margins are remaining the same, but season, nobody can predict. As far as digestive portfolio is concerned, Hajmola has grown by 9%. Variants contributing 50%. We launched soft chews, and we are modernizing the portfolio. To your point that we are modernizing, and 50% of the portfolio is now variants. It is just not regular and AM variant. It's all Limcola, Chatcola, which are all modern, quite urban-centric portfolio, which is resonating with the new consumer.
We can see the light at the end of the tunnel. Soft chews are doing well for us. Pudin Hara, 7% growth, with Lemon Fizz, which is a newer powder format, is growing by something like around 60%. The new communication of acidity relief is again adding to the growth momentum of Pudin Hara. In OTC and ethicals, there is Honitus, which is a brand. It's grown by around 46% because of the cough and cold season and virus. Hot Sip, newer format of Honitus, 95% growth. Our new initiative of health juices has gone up by 18%. Lal Tail as a brand got impacted in UP and Bihar with a small player called ED Oil, and he took away our market share. Suddenly, a new player has come in, and we will correct that situation, which is a very localized problem, which has been identified, and we've corrected it.
There has been market share loss in our Lal Tale business, which we will correct going forward. Shilajit, in secondary terms, is growing by 10%, but because of competitive intensity, we had to give schemes, so you don't see so much of growth here. We have also exited Diapers and Tea and One More and Vita. These three brands, which contributed to around INR 8 crore of business, we discontinued as part of our vision exercise. That has led to a little bit of pushback on the absolute growth in healthcare, which we did as a part of our cutting the tail and providing focus on the core brands. I don't think there is any problem. Glucose was also cycling a very high base of 31% and now declined by 40% because of rains and very centric. That is the only outlier here.
Otherwise, I think healthcare is on a very strong trajectory of growth. I don't think there is any concern on this end.
Mohit, from that base, post-COVID, I was looking at a slightly longer-term trend. The question was more towards, is the communication relevant to the newer or younger population? Is there a habit change? At the end of the day, we all understand post-COVID, there was a high base. It's been now three or four years, the category is more or less stagnant. I was looking for that, not necessarily this specific quarter from a number perspective. Directionally, how will the growth come back? This is where our margins are highest. This is where our moat is. This is where our leadership is. Beyond the point of time, if the core engine doesn't fire, the overall growth could be muted despite the base, is what I was trying to understand.
Yeah, so long-term also, we are operating. See, you have to understand where are we operating. We are operating in segments of cough and cold. Cough and cold market is huge. Our market share is very low, and we compete against allopathic brands. Ayurvedic is gaining traction. Therefore, Honitus is very, very well poised to grow to the next level and taking share from Ayurvedic upside because consumers are moving back to nature and natural. Now, the second segment, which we are present in, is digestion. In digestion, we have two brands called Hajmola and Pudin Hara. Again, they are growing very well. One is an appetizer, which ignites hunger, and the other is a stomach ailment and handles acidity. ENO is a big brand. Again, market share gains are consistently happening. The third is health juices that we introduced. We are steering it to around INR 1 billion.
Again, long-term trend and growing exceedingly well. Baby care, Lal Tail, again, very well positioned. Shilajit, the men's care brand, as you know, Kapiva is the new startup, which is really taking the category to a new level and growing now for gym care, sorry, gym goer population also. That's doing well. Glucose targets the energy-giving population. As you know, Unilever also launched an IV liquid, which is catering to this, and most of the brands, electrolytes, are again targeting this market. That is where Glucose is. Again, no concern on that. Honey is doing well. We have got 50% share. Another 50% share is there, and honey penetrations in the country are low. We are continuously driving honey on positioning of weight management, that is, and low sugar and non-sucrose and more fructose and energy-giving. That's doing well.
DCP, again, new formats are the ones which are driving that growth. I don't think there is a long-term any concern. The new generation is using newer formats. When you see new generation, new generation is 10% of the population on e-commerce and quick commerce that you see, which is 10% of the industry. That 10% should not make a perception in you that 90% of the market is following 10% and these categories are not doing well. There is some winter or sometimes summer, I think, poses a little obstacle to growth, but that should not be seen as a long-term trend in my view. That's the take which I have. Yeah.
Sure. Thanks. I'll join back if I have more questions. Thank you.
Thank you. Before we take the next question, I would request the members of the management to come closer and speak, please, so that we have optimum audio quality in the conference. Thank you. You may please press Star and want to ask questions. The next question is from the line of Aditya Vikram from Digital Securities Private Limited. Please go ahead.
Hi, Mohit. Am I audible?
Yes, sir. Please proceed.
Hi. Star is in a good set. It seems like, at least sequentially, we are doing well. It seems like people are still not happy, so can't really comment on that front. I missed when you were initially giving a guidance. Considering the festive season, rain should go away in a month or two, and rural segments firing. What was the guidance? You said we will grow in double-digit. The first one, can you clarify that again, please?
Aditya, we could not hear you. There's a lot of disturbance in your line. Could you please repeat the question?
Sorry. Am I audible now?
Is it [crosstalk]?
Mohit, congrats on a good.
Hello? There's too much glare in the voice. We can't hear.
Please give me a moment. Let me also check.
Is it better? Any better?
No, not really.
You may proceed now. You may try now.
Is it better now?
We can try.
Okay. I'll try to be as loud as possible. Apologies if it is still not clear. What I was saying is that congrats on a good set. Sequentially, it looks like a good performance. Still, people are not happy, so can't do much about that. I missed your answer on the first question, which was asked by one of the analysts. What would be the growth guidance from here? I heard that you said beverages might not do great, but what about the other segments?
Yeah. We are expecting, I think you're talking about the guidance going forward for the full year. Full year, we are looking at a guidance of high single-digit kind of a growth for the full year. For the coming quarter, because the base was low, we should be looking at a double-digit growth. Beverage seems to be under pressure, and that may have a low single digit. Other parts of the verticals should be growing at double-digit, going to a lower base, and also urban-rural both doing well for us and be gaining market shares across the board. I have no doubt that other two verticals should have a double-digit growth. The month of July has been very wet, and the beverage part of the business hasn't done too well in the month of July. That's the only remark. Yeah.
Okay. Thanks. In terms of this quarter performance, could you please give a breakup of volume versus price differentials?
Yeah. Basically, volume is low single digit, around - 1%. Price increase is 3%, but most of it got negated because of heightened competitive intensity. Therefore, the net realization was -1 1.8% in India.
Okay. What would be—so you mentioned earlier that you're not seeing inflationary pressure. Do we suffer more price hike in terms of volume and everything else?
Sorry, Aditya, your voice is breaking right now. Can you repeat your question, please?
What I was trying to ask is that, are you satisfied where these levels are right now, or do you see price hikes in the coming quarter?
Yeah. What we are seeing is more inflationary pressure, especially in the edible oils category. Consequently, we have either taken price increases, fresh price increases apart from the rollover price increases, or heightened our saving initiatives program going forward as well. We expect that at least before netting, we would be able to protect our margins despite 7- 8% inflation before netting.
Okay. Okay. Okay. Understood. Thank you very much. Congrats on a good set. I hope you do all the best in the coming quarters with festive season and everything coming along.
Thank you, Prakash. Thank you, Aditya. Sorry.
Thank you, sir. The next question is from the line of Tejas Shah from Evindus Park. Please go ahead.
Hi. Thanks for the opportunity. Mohit, I just have one broader question. When you step back and look at the portfolio more broadly and then not related to monsoon or summer seasonality, which comes and goes, is there a strategic stencil or framework you are now using to shape the next two, three years of growth? How are you thinking about where to double down, where to dial back from here, or which category? When you said high single digit, I'm assuming some of the categories have to deliver double-digit growth also. Which those categories would be and which will be the kind of under-index on that number?
Yeah. As you know, we conducted a vision exercise recently, and there are seven big moves that I communicated also. The first one is to double down on our core brands, which contribute around 60% - 70% of the business, which are INR 700 crore plus, which will contribute to our growth. We are spending 70 bps higher in the first quarter also investment, which is oral care, which is Dabur Red. We are planning to flag Dabur Red to other benefit gaps which are there in the segment. The second is Dabur Amla, of course, is doing well. We invested on Dabur Amla to gain market share. Now we want to contemporize and premiumize the brand going forward. That's the second pillar. Third is also home care, which is already market is growing at around double-digit. We have introduced LBP, and LBPs are doing well.
That's what one will do. Skincare is also, so HVC broadly, and also healthcare. We have identified four brands I talked about, which is where we'll be doubling down on. Those four brands are Pudin Hara, Health Juices, Hajmola, and Shilajit. We want to all scale them up to around INR 100 crore and Hajmola moving up to around INR 550 crore. We are also conducting a GTM exercise for us to improve the ROI of the GT distributors and the price equilibrium and increasing span of control, etc. All the same, I think whatever gaps in the portfolio are that we want to plug through M&A, and we are continuously scouting for targets for M&A, which are maybe new age, which will fortify our existing portfolio with some new age brands in healthcare, HVC, and the food or beverage area in all the three verticals which we are planning.
That's a very big picture, broad brush on our portfolio where we'll be wanting to scale up the business. I think the low-hanging fruit for us is definitely oral care, home skin care, and also hair care innovations going forward. Yeah.
Thanks. Thanks for the detailed answer. Just one follow-up on that. On M&A, what we have seen with some of the peers is that they have created 20%-2 5% of their portfolio of D2C brands, and that segment is kind of growing at 20%- 25% to cover up the 5%- 6% of overall growth. When you talk about M&A, will we be going in some of the new categories, which is largely on the wellness side, or will it be more premiumization in the existing portfolio that we have?
No, we are basically looking at wellness. Wellness foods, wellness health, that kind of M&As is what we are intending to look at. M&A is very chance-based depending upon what is available. Definitely premium, which is margin equitative to our base business so that it improves our margins going forward. We understand for a couple of years there may be investment, but there should be a path to profitability which should be equitative to our base profits.
Got it. That's all from my side. Thanks.
Thank you.
Thank you. The next question is from the line of Gaurang Kakkar from Centrum Broking. Please go ahead.
Yeah. Hi. Thanks for the opportunity. Mohit, firstly, on the volume part, you mentioned the volume on a reported basis is 1% degrowth, right? If we have to look at it X of seasonal business, the 7% growth, what will be the volume growth in that portfolio?
Volume growth is 3%. 3% - 3.5% is our volume growth if you look at the 7% ex-seasonal portfolio.
Okay. Got it. Secondly, you mentioned, and obviously we all know that last year was an inventory correction year for us at the GT level. Now, is that largely exercise done? FY2026, whatever secondary growth we get will largely be reflected in terms of primary growth?
Yes, Gaurang. We don't intend to do any more inventory correction going forward. It's already been done. We are sitting at around 21 -2 2 days depending on product category inventory, and we think with our diversified portfolio and the seasonality that we have, this is the optimal level of inventory that we have. The stockists are making good ROI. While we are conducting a GTM exercise, which will be all about consolidation, increasing span of control, etc., inventory levels are pretty much very similar.
Okay. Thanks for that. Just finally, one thing on the guidance front. You've given largely the top-line guidance and broken it up into the beverages and the non-beverage portfolio. In terms of margins, you mentioned that at the gross margin level, we see some improvement on a full-year basis. At the EBITDA front, largely, are we expecting improvement, or most of it will be reinvested in A&P and EBITDA on a full-year basis would largely be flat?
No. We are working towards significant improvement of operating margin as compared to last year. If you look at the first quarter, despite the high inflation, our operating margins have been maintained. As we embark upon premiumization and a better mix and contemporization of portfolio, I think these margins will only improve going forward. At this year's end, we expect operating margins to move up significantly from last year to this year. That's the intent, and that's the target that we have taken.
Perfect. Yeah, that's it from my end. Thanks a lot.
Thank you.
Thank you. You may please press star and one to ask questions. The next question is from the line of Alokitha Ash from Goldman Sachs. Please go ahead.
Hi. Am I audible?
Yes, ma'am. Please proceed.
I have a question on the oral care. I understand you said that there have been gross margin pressures due to Colgate being super competitive and you having to give distributors—I mean, you have to increase promotional spend. How has the toothpaste growth been much stronger than the market leader, which is Colgate? Have there been any other initiatives which are driving this outperformance? Do you expect this to continue?
Yeah. We expect oral care category growth is around 4%. We are much substantially higher than the category growth as far as nutrient data is concerned. Plus, there is a tailwind on the herbal, natural category, which is growing at 2 x the non-herbal category. Non-herbal category is growing at 4.4%. The herbal category is growing at 8.8%. We are by far the market leaders in the herbal, natural line within the category. We continue to grow. Our Red franchise has grown at around 9% secondary and 8% eye gap sales. Miswak is growing by around 5%. Our Dabur herbal toothpaste, which is a new franchise, is growing at 30%. We expect oral care to keep firing at the same momentum as it has been in the first quarter. That is a category which we are double-doubting on. We have taken, as you know, Amitabh Bachchan as one.
Plus, we embarked on an anti-fluoride campaign, which is also working very well for us across different regions. On the back of which, we are gaining market share. We gained around 14 bps market share in the current quarter, which takes our market share up to around 16.6%. We are very confident on improving trajectory in oral care going forward.
Thank you.
Thank you. As there are no further questions, I would now like to hand the conference over to Ms. Isha Lamba for closing comments. Thank you, and over to you, ma'am.
I would like to thank all the participants for joining today's call. The webcast recording and transcript will be available on our website. Thank you, and have a great evening ahead.
Thank you, members of the management. On behalf of Dabur India Limited, that concludes this conference. We thank you for joining us, and you may now disconnect your lines. Thank you.